NEW YORK (GenomeWeb News) – Myriad Genetics said this week that BioMarin Pharmaceutical will use its BRACAnalysis test in its pivotal Phase 3 clinical study for BMN 673, an orally active PARP-inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad has submitted an Investigational Device Exemption to the US Food and Drug Administration that would allow the BRACAnalysis test to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program, as required by FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.